Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
cd22 car-transduced t cells B-Cell Non-Hodgkin Lymphoma	Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology	P1/2	B (58)
Cart-19 Cells Burkitt Lymphoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P3	B (57)
Rondecabtagene Autoleucel Diffuse Large B-Cell Lymphoma	Lyell Immunopharma, Inc.	P3	B (57)
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Chronic Myeloid Leukemia	Leland Metheny	P2	B (57)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Acute Myeloid Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2	B (57)
Anti-Cd7 Car-T Hematopoietic And Lymphoid System Neoplasm	Institute of Hematology & Blood Diseases Hospital, China	P2	B (57)
Brexucabtagene Autoleucel Mantle Cell Lymphoma	Vanderbilt-Ingram Cancer Center	P2	B (57)
cd19-ucart Refractory T Lymphoblastic Leukemia/Lymphoma	Beijing Boren Hospital	P2	B (57)
cd19-ucart Relapse/Recurrence	Beijing Boren Hospital	P2	B (57)
cd19-ucart T-cell Leukemia/Lymphoma	Beijing Boren Hospital	P2	B (57)
Hst-Neets HIV-Associated Cancer	Catherine Bollard	P2	B (57)
Lactobacillus Gasseri Bgp345A Opioid-Induced Constipation	BioGaia Pharma AB	P2	B (57)
Lifileucel Cancer	Hervor Therapeutics	P2	B (57)
Lifileucel Soft Tissue Sarcoma	Iovance Biotherapeutics, Inc.	P2	B (57)
Murine Autologous Anti-Cd19 Chimeric Antigen Receptor T Cells Acute Lymphoblastic Leukemia	Beijing Boren Hospital	P2	B (57)
Murine Autologous Anti-Cd19 Chimeric Antigen Receptor T Cells Childhood Acute Lymphoblastic Leukemia	Beijing Boren Hospital	P2	B (57)
Tabelecleucel Post-Transplant Lymphoproliferative Disease	Pierre Fabre Medicament	P2	B (57)
TIL Lung Cancer	Essen Biotech	P2	B (57)
Anti-Cd19/Cd22 Car-T Cells Acute Lymphobkastic Leukemia	Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology	P1/2	B (57)
cd19-ucart Refractory B Acute Lymphoblastic Leukaemia	National University of Malaysia	P2/3	B (57)
cd19-ucart Precursor B-Cell Acute Lymphoblastic Leukemia	National University of Malaysia	P2/3	B (57)
Dc-Cik Advanced Cancer	University of Malaya	P2/3	B (57)
Ngfr-Transduced Autologous T Lymphocytes Cutaneous Melanoma	M.D. Anderson Cancer Center	P1/2	B (57)
Tvi-Brain-1 Brain Glioblastoma	TVAX Biomedical	P2/3	B (57)
Lifileucel Melanoma	Iovance Biotherapeutics, Inc.	P3	B (56)

Showing 151 to 175 of 3,774 assets

PreviousPage 7 of 151Next